Rate this article:
Thanks for supporting the BJUI in your international capacity. Please comment on the FREE articles of the week.
I agree to the Terms & Conditions
Notify me of follow-up comments by email.
Notify me of new posts by email.
Please note that all submitted comments will be reviewed by the BJUI Web Team before they are considered for publishing on the site. Comments may take up to 48 hours to go live. If you have made a comment which has not appeared live after this time and you wish to discuss this matter further, please contact us.
This week’s featured video: Safety and efficacy of mirabegron as ‘add-on’ therapy in patients with OAB treated with solifenacin – Click here for more
Tweets by @BJUIjournal